Skip to content
Open access

Is It Feasible to Assess Clinical Remission in Asthma via a Customized Data Extraction Approach from a Real-World Clinical Electronic Medical Records Database in Japan? A Retrospective Real-World Study.

Sep 2026 · Journal of Asthma · pp. 1-18 · 0 citations · 18 references
Medicine

TL;DR

It may be feasible to assess CR using EMR data in Japanese patients with asthma, however, infrequent recording of CR components in clinical practice, particularly ACT and lung function tests, limits availability of EMR data for CR assessments and the potential generalizability of CR findings.

Abstract

Objective: Clinical remission (CR) is an ambitious and attainable treatment goal for patients with asthma. This retrospective, observational study determined the feasibility of assessing CR using an electronic medical record (EMR) database. Methods: Data from the JAMDAS database were analyzed for patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024. Asthma Control Test (ACT) scores were extracted using structured query language. For exacerbations, hospitalization and emergency transport data were extracted using a large language model. The proportion of patients meeting Japanese Practical Guidelines for Asthma Management 2024 CR definition (oral corticosteroid [OCS]-free, no exacerbations, ACT ≥ 23), treatment patterns, adherence and persistence were assessed at 3-month intervals until 18-months post-initiation. Additionally, forced expiratory volume in 1 second (FEV1%)/forced vital capacity and fractional exhaled nitric oxide (FeNO) test frequency were extracted. Results: Of 32 258 eligible patients, only 1.8-3.0%, 0.5-1.5% and 4.5-10.1% had 3- to 18-month ACT, FEV1% or FeNO data available. Among patients with 3-month ACT data (2.9% [n = 934/32 258]), 98.6% (n = 921/934) had no exacerbations and 81.0% (n = 757/934) had no OCS use. Among evaluable patients (3-months: 2.9%; 18-months: 3.0%), 41.1% (n = 384/934) met all CR components at 3-months and 69.3% (n = 199/287) at 18-months post-initiation. Conclusions: This study suggests it may be feasible to assess CR using EMR data in Japanese patients with asthma. However, infrequent recording of CR components in clinical practice, particularly ACT and lung function tests, limits availability of EMR data for CR assessments and the potential generalizability of CR findings. Funding: GSK (Study 222904).

Read PDF

Similar papers

Open access Sep 2026

Assessing the impact of earlier initiation of biologics on clinical remission and other outcomes in a global real-life severe asthma cohort from CHRONICLE, ISAR and OPCRD.

BACKGROUND Biologics are generally reserved for severe asthma (SA) after standard treatments have failed. Their recommendation is based on randomized controlled trials, designed to assess efficacy but not the optimal timing for biologic initiation. RESEARCH QUESTION Does the timing of biologic initiation affect SA ou...

G. Canonica, G. Christoff, Ming-Ju Tsai et al. · 0 citations
Open access Aug 2026

Identification and longitudinal evaluation of inhaled medication adherence barriers using clinical natural language processing in asthma: a real-world cohort study

Background To develop a rule-enhanced clinical natural language processing (clinical NLP) framework for the automated identification of inhaled medication adherence barriers in asthma, characterize their longitudinal trajectories, and evaluate their associations with longitudinal medication adherence. Methods This real...

Chun-Juan Zhang, Jia-Heng Lu, Xiu-Juan Ma et al. · 0 citations
Open access Oct 2026

Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1

Purpose Asthma affects 26 million individuals in the US, with severe cases driving high healthcare use and costs. TezspireTM (tezepelumab) has shown benefits in a Phase 4 real-world study, but real-world claims-based evidence is limited. This study evaluated the real-world effectiveness of tezepelumab by assessing chan...

Santiago Zuluaga Sanchez, J. Demartino, M. Gorritz et al. · 0 citations
Aug 2026

Persistent uncontrolled severe asthma despite widespread biologic use: care gaps from the French FASE2-CPHG real-world study.

BACKGROUND Biologic therapies have transformed the management of severe asthma, yet many patients in routine care remain symptomatic. Most real-world data originate from tertiary centers and may not reflect broader healthcare delivery. OBJECTIVE To describe disease control, exacerbations, adherence, comorbidities, ph...

L. Portel, C. Nocent-ejnaini, É. Parrat et al. · 0 citations
Open access Aug 2026

A prospective observational study to evaluate the prevalence of severe asthma among subjects with difficult-to-treat asthma at a tertiary care center in North India

Background: Severe asthma accounts for disproportionate asthma-related morbidity, mortality, and healthcare costs, yet prospective data on its prevalence remain limited, particularly for developing countries. We aimed to determine the prevalence of severe asthma among subjects with difficult-to-treat asthma at a tertia...

Sandeep Sharma, R. Agarwal, V. Muthu et al. · 0 citations
Review Open access Sep 2026

Using an Electronic Medical Record to Evaluate Pediatric Blood Pressure Follow-Up: Limitations of Automated Data Extraction in a Nephrology Cohort

Hypertension is a prevalent condition in the pediatric population. Diagnosis and management can be challenging. The widespread adoption of electronic medical records (EMRs) has revealed their potential for improving patient care and research. This study used EMR data from the nephrology clinic at a single ce...

R. Mah, A. Tsampalieros, R. Webster et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.